Dietary Salt Intake Is a Determinant of Cardiac Changes After Treatment of Primary Aldosteronism: A Prospective Study

Primary aldosteronism is associated with increased left ventricular (LV) mass independently of blood pressure. Previous studies suggest that elevated aldosterone causes cardiac damage only in the presence of an inappropriate salt status. We examined the relevance of dietary salt intake on cardiac changes in patients with primary aldosteronism before and after treatment. Sixty-five patients with tumoral or idiopathic primary aldosteronism were recruited at a University medical center and followed after either surgical (n=30) or medical (n=35) treatment. At baseline and 1 year after treatment, cardiac morphology and functional variables were measured by echocardiography together with duplicate 24-hour urinary sodium collections. At baseline, LV mass index was associated with urinary sodium excretion and plasma aldosterone levels. During follow-up, blood pressure (from 167/102–135/83 mm Hg; P<0.001) and LV mass index (from 50.5±13.0–44.4±8.9 g/m2.7; P<0.001) decreased significantly with nonsignificant changes in LV geometry and functional properties. At the end of follow-up, percentage decrease in LV mass index was significantly greater in patients who had >10% reduction in urinary sodium excretion (15.0±12.5%) than in the remaining patients (5.5±9.3%; P<0.001). Changes in LV mass index induced by both surgical and medical treatment were directly and independently correlated with changes in blood pressure (&bgr;=0.419; P=0.009) and urinary sodium excretion (&bgr;=0.334; P=0.012) observed at follow-up. These findings strongly support the hypothesis that dietary salt intake has a crucial role in aldosterone-related LV changes and could contribute to cardiac damage in patients with primary aldosteronism.

[1]  L. Sechi,et al.  Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension. , 2015, American journal of hypertension.

[2]  M. Novello,et al.  Aldosterone and Left Ventricular Remodeling , 2015, Hormone and Metabolic Research.

[3]  L. Sechi,et al.  Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Naïve Patients With Hypertension: Tissue-Doppler Imaging Study , 2015, Hypertension.

[4]  L. Sechi,et al.  Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. , 2015, American journal of hypertension.

[5]  J. Funder.  Primary aldosteronism and salt , 2014, Pflügers Archiv - European Journal of Physiology.

[6]  C. Catena,et al.  Salt, Hypertension, and Cardiovascular Disease , 2014 .

[7]  C. Catena,et al.  Aldosterone, organ damage and dietary salt , 2013, Clinical and experimental pharmacology & physiology.

[8]  F. Veglio,et al.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[9]  L. Sechi,et al.  Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels. , 2013, American journal of hypertension.

[10]  M. Stowasser,et al.  Salt, aldosterone and hypertension , 2013, Journal of Human Hypertension.

[11]  C. Catena,et al.  Aldosterone and the Heart: From Basic Research to Clinical Evidence , 2011, Hormone and Metabolic Research.

[12]  R. Wachter,et al.  Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. , 2012, European heart journal.

[13]  R. Carey.  Double-barreled assault by aldosterone and salt on the heart. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  T. Marwick,et al.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  C. Catena,et al.  Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. , 2010, American journal of hypertension.

[16]  P. Fesler,et al.  Dietary Sodium, Aldosterone, and Left Ventricular Mass Changes During Long-Term Inhibition of the Renin-Angiotensin System , 2010, Hypertension.

[17]  M. Herregods,et al.  Independent Relations of Left Ventricular Structure With the 24-Hour Urinary Excretion of Sodium and Aldosterone , 2009, Hypertension.

[18]  X. Jeunemaître,et al.  Dietary sodium alters the prevalence of electrocardiogram determined left ventricular hypertrophy in hypertension. , 2009, American journal of hypertension.

[19]  M. Bazzocchi,et al.  Intrarenal hemodynamics in primary aldosteronism before and after treatment. , 2009, The Journal of clinical endocrinology and metabolism.

[20]  F. Beuschlein,et al.  Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. , 2009, The Journal of clinical endocrinology and metabolism.

[21]  D. Levy,et al.  Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry , 2008, Circulation.

[22]  D. Rizzoni,et al.  Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism , 2008, Hypertension.

[23]  C. Yabe-Nishimura,et al.  Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1 , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  P. Strazzullo,et al.  Primary aldosteronism: cardiovascular, renal and metabolic implications , 2008, Trends in Endocrinology & Metabolism.

[25]  H. Matsubara,et al.  Aldosterone Nongenomically Produces NADPH Oxidase–Dependent Reactive Oxygen Species and Induces Myocyte Apoptosis , 2008, Hypertension Research.

[26]  L. Sechi,et al.  Cardiovascular outcomes in patients with primary aldosteronism after treatment. , 2008, Archives of internal medicine.

[27]  S. Mccune,et al.  Salt-Induced Cardiac Hypertrophy Is Independent of Blood Pressure and Endothelin in Obese, Heart Failure-Prone SHHF Rats , 2008, Clinical and experimental hypertension.

[28]  J. Funder.  Mineralocorticoid receptor activation and oxidative stress. , 2007, Hypertension.

[29]  L. Sechi,et al.  Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism , 2007, Hypertension.

[30]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[31]  R. Schmieder,et al.  High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene , 2007, Journal of hypertension.

[32]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[33]  A. Yamashina,et al.  Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[34]  J. Sowers,et al.  Hypertension and Cardiovascular Disease , 2006 .

[35]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[36]  J. Sharman,et al.  Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. , 2005, The Journal of clinical endocrinology and metabolism.

[37]  J. Funder.  Is aldosterone bad for the heart? , 2004, Trends in Endocrinology & Metabolism.

[38]  W. Young,et al.  Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents , 2004 .

[39]  N. Reichek,et al.  Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential , 2003 .

[40]  Ricardo Rocha,et al.  Aldosterone induces a vascular inflammatory phenotype in the rat heart. , 2002, American journal of physiology. Heart and circulatory physiology.

[41]  C. Otto,et al.  Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[42]  G. Adler,et al.  Cardiac Damage Prevention by Eplerenone: Comparison With Low Sodium Diet or Potassium Loading , 2002, Hypertension.

[43]  M. Tordoff,et al.  Different effects of three aldosterone treatments on plasma aldosterone and salt intake , 1993, Physiology & Behavior.

[44]  J. Laragh,et al.  Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. , 1992, Journal of the American College of Cardiology.

[45]  T. Ogihara,et al.  Increase in plasma ouabainlike inhibitor of Na+, K+-ATPase with high sodium intake in patients with essential hypertension. , 1987, Journal of clinical hypertension.

[46]  R. Sloan,et al.  Estimating Dietary Sodium Intake in Individuals Receiving a Randomly Fluctuating Intake , 1982, Hypertension.

[47]  R. Gaunt,et al.  Aldosterone and hypertension. , 1957, Archives internationales de pharmacodynamie et de therapie.